Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group.
Quirt I, Bodurth A, Lohmann R, Rusthoven J, Belanger K, Young V, Wainman N, Stewar W, Eisenhauer E; National Cancer Institute of Canada Clinical Trials Group. Quirt I, et al. Among authors: belanger k. Invest New Drugs. 2002 Nov;20(4):431-7. doi: 10.1023/a:1020625423524. Invest New Drugs. 2002. PMID: 12448662 Clinical Trial.
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
Lee CW, Bélanger K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N, Seymour L. Lee CW, et al. Among authors: belanger k. Invest New Drugs. 2008 Jun;26(3):249-55. doi: 10.1007/s10637-007-9097-9. Epub 2007 Oct 26. Invest New Drugs. 2008. PMID: 17962907 Clinical Trial.
Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole.
Bélanger K, Jolivet J, Maroun J, Stewart D, Grillo-Lopez A, Whitfield L, Wainman N, Eisenhauer E. Bélanger K, et al. Invest New Drugs. 1993 Nov;11(4):301-8. doi: 10.1007/BF00874428. Invest New Drugs. 1993. PMID: 8157472 Clinical Trial.
Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.
Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, Soulieres D, Stewart D, Goel R, Charpentier D, Goss G, Tomiak E, Yau J, Jimeno J, Chiritescu G; National Cancer Institute of Canada Clinical Trials Group. Maroun JA, et al. Among authors: belanger k. Ann Oncol. 2006 Sep;17(9):1371-8. doi: 10.1093/annonc/mdl165. Ann Oncol. 2006. PMID: 16966366 Free article. Clinical Trial.
Interleukin-21 has activity in patients with metastatic melanoma: a phase II study.
Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, Kamel-Reid S, Tron V, Chen BE, Hunder NN, Hagerman L, Walsh W, Eisenhauer EA. Petrella TM, et al. Among authors: belanger k. J Clin Oncol. 2012 Sep 20;30(27):3396-401. doi: 10.1200/JCO.2011.40.0655. Epub 2012 Aug 20. J Clin Oncol. 2012. PMID: 22915661 Clinical Trial.
NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).
Gertler SZ, MacDonald D, Goodyear M, Forsyth P, Stewart DJ, Belanger K, Perry J, Fulton D, Steward W, Wainman N, Seymour L. Gertler SZ, et al. Among authors: belanger k. Ann Oncol. 2000 Mar;11(3):315-8. doi: 10.1023/a:1008336607135. Ann Oncol. 2000. PMID: 10811498 Free article. Clinical Trial.
245 results